Healthcare / BiotechnologyNasdaqCM
$0.62
+0.01 (+1.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-6.1M · quality 76.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$15M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-398.1%
↓Gross Margin
99.6%
↑Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-1494.5%
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $705923.0 · net income $-11.9M · FCF $-10.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $705923.00 | $705923.00 | $464278.00 | $226208.00 | $255397.00 | $722738.00 | $384543.00 | $222610.00 | $433287.00 | — | — | — | — | — | — | — | — |
| Net Income | $-11.9M | $-11.9M | $-5.8M | $-6.7M | $-7.3M | $-4.0M | $-4.1M | $-4.2M | $-6.6M | $-1.9M | $-1.3M | $-2.0M | $-1.6M | — | — | $-538226.00 | $-552462.00 |
| EBITDA | $-11.8M | $-11.8M | $-5.7M | $-6.4M | $-6.5M | $-5.6M | — | — | — | — | — | — | — | — | — | — | — |
| EPS | -0.66 | -0.66 | -0.47 | -1.01 | -1.24 | — | — | — | — | — | — | — | — | — | — | -0.04 | -0.04 |
| Gross Margin | 99.6% | 99.6% | 99.0% | 86.1% | 71.9% | 75.7% | 56.0% | 89.7% | 94.2% | — | — | — | — | — | — | — | — |
| Operating Margin | -1683.0% | -1683.0% | -1239.2% | -2888.5% | -2591.7% | -786.8% | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | -1686.0% | -1686.0% | -1248.2% | -2946.4% | -2846.3% | -557.2% | -1062.2% | -1868.0% | -1525.4% | — | — | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 0.04 | 0.04 | 0.02 | 0.05 | 0.01 | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 26.88 | 26.88 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-10.6M | $-10.6M | $-5.1M | $-6.1M | $-5.1M | — | $-2.6M | $-3.7M | — | $-1.5M | $-663950.00 | $-1.5M | — | — | — | — | — |
| Returns | |||||||||||||||||
| ROE | -398.1% | -398.1% | -72.1% | -218.9% | -91.5% | -30.4% | -164.6% | -167.0% | -276.7% | -69.7% | -480.1% | -256.8% | -90.8% | — | — | -20.2% | -25.7% |
| Valuation | |||||||||||||||||
| P/B | 3.76 | 3.76 | 4.82 | 2.17 | 2.21 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | 52.0% | 52.0% | 105.2% | -11.4% | — | 87.9% | 72.7% | -48.6% | — | — | — | — | — | — | — | — | — |
| EPS Growth | -40.4% | -40.4% | 53.5% | 18.5% | — | — | — | — | — | — | — | — | — | — | — | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-36.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.47 → -0.66
Residual
-36.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.